Back to search
A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option
Hypertension, Pulmonary
Clinicaltrials.gov:
EU CTIS:
#2023-506791-27-00
EudraCT:
J&J ID:
#CR109121
Other:
#NOPRODPAPUH3001
Interested in this trial?
Subscribe or share this trial
Trials at a glance
Status
Enrolling
Condition
Hypertension, Pulmonary
Trial type
Interventional
Trial phase
Phase 3
Investigational
product
product
Macitentan
Macitentan/Tadalafil FDC
Selexipag
Age
2+ years old
Biological sex
All
Placebo?
No
Trial start date
May 4, 2022
Trial end date
March 30, 2029
CT.gov ID
#NCT05179876
Share the trial ID with your doctor to see if trial participation is right for you. Participation depends on an independent medical assessment.
Countries:
- Belarus,
- Belgium,
- Bulgaria,
- China,
- Hungary,
- Poland,
- Russia,
- South Africa,
- South Korea,
- Taiwan,
- Thailand,
- Ukraine,
- Vietnam
Loading...
Enrolling
Seoul, South Korea, 05505
Enrolling
Beijing, China, 100029
Enrolling
Beijing, China, 100029
Enrolling
Taoyuan, Taiwan, 333
Enrolling
Ho Chi Minh City, Vietnam
Enrolling
Shanghai, China, 200062
Enrolling
Daejeon, South Korea, 35015
Enrolling
Lenasia, South Africa, 1820
Enrolling
Novosibirsk, Russia, 630055
Enrolling
Incheon, South Korea, 21565
Enrolling
Budapest, Hungary, 1096
Enrolling
Hanoi, Vietnam
Enrolling
Hanoi, Vietnam
Enrolling
Nanjing, China
Enrolling
Kaohsiung City, Taiwan, 813
Enrolling
Bialystok, Poland, 15 276
Enrolling
Chiang Mai, Thailand, 50200
Enrolling
Minsk, Belarus
Enrolling
Tainan, Taiwan, 704
Enrolling
Taipei, Taiwan, 100
Enrolling
Lodz, Poland, 91 347
Enrolling
Qingdao, China, 266035
Enrolling
Tyumen, Russia, 625000
Enrolling
Katowice, Poland, 40 635
Enrolling
Szczecin, Poland, 70 111
Enrolling
Seoul, South Korea, 06351
Enrolling
Seoul, South Korea, 03080
Enrolling
Seoul, South Korea, 03080
Enrolling
Taipei, Taiwan, 112
Enrolling
Xi'an, China, 710061
Enrolling
Minsk, Belarus, 220036
Enrolling
Changsha, China, 410011
Enrolling
Sofia, Bulgaria, 1750
Enrolling
Wroclaw, Poland, 51 124
Completed
Durban, South Africa, 4001
Completed
Saint Petersburg, Russia, 197341
Completed
Tomsk, Russia, 634012
Completed
Dnipro, Ukraine
Completed
Kemerovo, Russia, 650002
Completed
Kyiv, Ukraine, 03680
Completed
Bydgoszcz, Poland, 85-168
Completed
Seoul, South Korea, 06591
Completed
Leuven, Belgium, 3000
Completed
Wroclaw, Poland, 51 124
Completed
Lublin, Poland, 20 718
#
More than 50 sites in this region
#
More than 10 sites in this region
#
Less than 10 sites in this region
Individual sites
Access detailed information on the trial:
Clinical trials information
© Johnson & Johnson and its affiliates 2026
